Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

---

Atıf İçin Kopyala

Ruperto N., Brunner H. I. , Quartier P., Constantin T., Wulffraat N. M. , Horneff G., ...Daha Fazla

ANNALS OF THE RHEUMATIC DISEASES, cilt.77, ss.1710-1719, 2018 (SCI İndekslerine Giren Dergi)

• Cilt numarası: 77 Konu: 12
• Basım Tarihi: 2018
• Doi Numarası: 10.1136/annrheumdis-2018-213150
• Dergi Adı: ANNALS OF THE RHEUMATIC DISEASES
• Sayfa Sayıları: ss.1710-1719

Özet

Objectives To evaluate the long-term efficacy and safety of canakinumab in patients with active systemic juvenile idiopathic arthritis (JIA).